BRD4 and hepatocellular carcinoma: Validation of CHK1 and BRD4 inhibitors, AZD7762 and OTX‐015, respectively, in three HCC‐PDXO lines have demonstrated that this combination exhibits synergistic interactions only in MYCHi HCC‐PDXOs.